Monitor the company's ability to control professional fees and manage cash burn, as the $7.1 million operating cash outflow raises sustainability concerns. Watch for progress on Nasdaq compliance following the recent AGM proposals, as failure to regain compliance could trigger delisting. The lack of patent protection for the MEDIFLY product, which generated 88.6% of 2025 revenue, represents a critical competitive vulnerability that investors should closely monitor.
Price Chart
Executive Summary
Cuprina Holdings reported a significant increase in net loss to $3.63 million in 2025, primarily due to a $3.1 million increase in operating expenses, particularly a $3.2 million surge in professional fees. Despite a modest 3.3% revenue increase driven by its MEDIFLY maggot therapy product, the company faces substantial challenges including lack of patent protection for its core product, significant working capital outflows, and ongoing Nasdaq compliance risks. Recent regulatory progress in Saudi Arabia and pipeline development in medical waste recycling and IVF media provide some strategic momentum.
Key Facts
- Net loss increased 198% from $1.56M in 2024 to $3.63M in 2025
- Revenue increased 3.3% from $48.3K to $49.9K, driven by MEDIFLY product sales
- Operating expenses surged 194% to $4.83M, with professional fees increasing by $3.2M
- Core MEDIFLY product has no patent protection, relying solely on trade secrets
- Net cash used in operating activities was $7.1M, a 478% increase from 2024
- Recent 6-K filings show company is addressing Nasdaq listing compliance through share consolidation
Financial Impact
Net loss increased by $2.11 million (198%) from 2024 to 2025, driven by a $3.1 million increase in professional fees and other operating expenses
Risk Factors
- Lack of patent protection for core MEDIFLY product makes it vulnerable to competition
- Significant cash burn from operations ($7.1M) threatens liquidity
- Nasdaq listing compliance at risk due to minimum bid price requirement
- Heavy reliance on professional fees ($3.2M increase) indicates high corporate costs
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 20-F Filing (Primary) | 0001493152-26-019085 |
| Exhibit: ex12-2.htm | 0001493152-26-019085 |
| Exhibit: ex12-1.htm | 0001493152-26-019085 |
| Exhibit: ex13-2.htm | 0001493152-26-019085 |
| Exhibit: ex13-1.htm | 0001493152-26-019085 |
| Document: 0001493152-26-019085-index-headers.html | 0001493152-26-019085 |
| Document: 0001493152-26-019085-index.html | 0001493152-26-019085 |
| Document: 0001493152-26-019085.txt | 0001493152-26-019085 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | 6-K | $1.93 | awaiting T+5 | — | $1.85 (+4.15%) |
Oct 2, 2026 25d ago | 6-K | $2.42 $1.69 | ▼ −30.17% | ▼ −31.33% | $1.85 (−23.55%) |
Oct 2, 2026 25d ago | Press Release | $2.42 $1.69 | ▼ −30.17% | ▼ −31.33% | $1.85 (−23.55%) |
Sep 29, 2026 28d ago | 6-K | $2.28 $1.99 | ▲ +12.72% | ▲ +14.63% | $1.85 (+18.86%) |
Sep 29, 2026 28d ago | Press Release | $2.28 $1.99 | ▲ +12.72% | ▲ +14.63% | $1.85 (+18.86%) |
Sep 18, 2026 5w ago | 6-K | $1.79 $1.87 | ▼ −4.47% | ▼ −3.20% | $1.85 (−3.35%) |
Sep 17, 2026 5w ago | 6-K | $1.79 $1.87 | ▼ −4.47% | ▼ −3.20% | $1.85 (−3.35%) |
Sep 17, 2026 5w ago | Press Release | $1.79 $1.87 | ▼ −4.47% | ▼ −3.20% | $1.85 (−3.35%) |
Sep 16, 2026 5w ago | 424B4 | $1.60 $1.88 | ▼ −17.50% | ▼ −15.68% | $1.85 (−15.63%) |
Sep 16, 2026 5w ago | EFFECT | $1.60 $1.88 | ▼ −17.50% | ▼ −14.94% | $1.85 (−15.63%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers